Azitra Inc
AZTR
查看详细走势图
0.318USD
+0.020+6.90%
收盘 12/24, 13:00（美东）报价延迟15分钟
1.78M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+6.90%
5天
+7.26%
1月
-1.70%
6月
-80.90%
今年开始到现在
-88.79%
1年
-88.31%
查看详细走势图
TradingKey Azitra Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Azitra Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名203/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价2.70。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Azitra Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
1
位分析师
买入
评级
2.700
目标均价
+603.13%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Azitra Inc亮点
亮点风险
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
Azitra Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Azitra Inc简介
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
公司代码AZTR
公司Azitra Inc
CEOSalva (Francisco D)
网址https://azitrainc.com/
常见问题
Azitra Inc(AZTR)的当前股价是多少？
Azitra Inc(AZTR)的当前股价是 0.318。
Azitra Inc的股票代码是什么？
Azitra Inc的股票代码是AZTR。
Azitra Inc股票的52周最高点是多少？
Azitra Inc股票的52周最高点是4.329。
Azitra Inc股票的52周最低点是多少？
Azitra Inc股票的52周最低点是0.278。
Azitra Inc的市值是多少？
Azitra Inc的市值是1.78M。
Azitra Inc的净利润是多少？
Azitra Inc的净利润为-8.97M。
现在Azitra Inc(AZTR)的股票是买入、持有还是卖出？
根据分析师评级，Azitra Inc(AZTR)的总体评级为买入，目标价格为2.700。
Azitra Inc(AZTR)股票的每股收益（EPS TTM）是多少
Azitra Inc(AZTR)股票的每股收益（EPS TTM）是-1.285。
相关品种
